Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GCK | P35557 | 9/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13477353 | 0.89 | GCK (0.40) | KMT2AMEN1GCKNPC1RAB9A | |
| SCHEMBL13477351 | 0.86 | NPC1 (0.48) | KMT2AMEN1GCKNPC1RAB9A | |
| SCHEMBL13477358 | 0.85 | GCK (0.51) | GCKNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL13477364 | 0.83 | GCK (0.40) | KMT2AMEN1GCKNPC1RAB9A | |
| SCHEMBL13477363 | 0.83 | GCK (0.40) | GCKNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL2208883 | 0.81 | GCK (0.57) | GCK | |
| SCHEMBL13477362 | 0.81 | GCK (0.35) | KMT2AMEN1GCKNPC1RAB9A | |
| SCHEMBL13477360 | 0.81 | GCK (0.48) | KMT2AMEN1GCKNPC1RAB9A | |
| SCHEMBL13477361 | 0.80 | NPC1 (0.40) | KMT2AMEN1GCKNPC1RAB9A | |
| SCHEMBL13477357 | 0.80 | NPC1 (0.36) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344003-B2 | 2-pyridinecarboxamide derivatives | MSD K. K. (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20100041660-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | MSD K.K. (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041660-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | GCKR, GCK, HK2 | KMT2A 1297/4885MEN1 4502/4885GCK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.